Inflammatory Challenge and Fear

PHASE1RecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
BIOLOGICAL

Typhoid VI Polysaccharide Vaccine Injectable Solution

Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.

OTHER

Saline Placebo (0.5mL injection)

The placebo injection will consist of 0.5mL of saline.

Trial Locations (1)

94121

RECRUITING

San Francisco VA Health Care System, San Francisco

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Northern California Institute of Research and Education

OTHER

collaborator

San Francisco Veterans Affairs Medical Center

FED

lead

University of California, San Francisco

OTHER

NCT06630884 - Inflammatory Challenge and Fear | Biotech Hunter | Biotech Hunter